

Notice to patients who participated in

JBCRG-09 and JBCRG-10 studies at participating hospitals

The general incorporated association JBCRG will use information from patients who participated in the above clinical studies for the study which details are given below. We would appreciate your understanding and cooperation in this regard.

| | |
|--|---|
| Study title | EBCTCG Meta-analysis |
| Principal study organization | EBCTCG (Early Breast Cancer Trialists' Collaborative Group) https://www.ctsu.ox.ac.uk/research/ebctcg |
| Study objectives | EBCTCG Meta-analysis is a large-scale integrated analysis of patients' background information and research data obtained through their participation in breast cancer clinical studies conducted worldwide. Its objectives are to investigate worldwide trends in breast cancer therapies, their efficacy and adverse effects, and examine breast cancer treatment modalities for the future. |
| Study subjects and types of information used | JBCRG received a request from EBCTCG to provide study data for patients who participated in JBCRG-09 "A randomized study of docetaxel + cyclophosphamide (TC), 5-fluorouracil + epirubicin + cyclophosphamide (FEC)-TC and TC-FEC as preoperative chemotherapy for hormone receptor positive and HER2 negative primary breast cancer" and JBCRG-10 "A randomized phase II comparative study of preoperative chemotherapies including trastuzumab + cyclophosphamide + docetaxel for operable HER2 positive breast cancer". The information to be provided is finalized data from the study that you participated, which include age, progression status and nature of cancer (e.g. tissue type, hormone receptor, HER2 expression) at the time of participation, as well as method of administration, dosage, efficacy and adverse effects of the study during the study period. These will be anonymized data from which individuals cannot be identified. The data will be recorded on CDs or DVDs and sent to EBCTCG in Oxford, UK where it will be integrated with that from large numbers of patients who have participated in breast cancer clinical trials worldwide and analyzed. |
| Non-agreement to use of data in the analysis | In order to provide your data, you will not need to undergo any additional research and it will not cost anything. If you have any questions about the analysis, please ask them by the end of September 2019. Please also let us know by this date if you do not wish your data to be used and it will not be included in the analysis. |

| | |
|---|--|
| Contact in case of non-agreement to use of data | Because JBCRG only has anonymized data on patients, it may be difficult to respond if you contact us directly. Please be sure to ask any questions or notify us of non-agreement to the use of your data through your attending physician at the medical institution participating in JBCRG-09/JBCRG-10. |
| Ownership of intellectual property arising from the study and conflicts of interest | EBCTCG, the principal study organization, retains the rights to any new findings or intellectual property arising from the study. Similarly, all rights to intellectual property arising from JBCRG-09 and JBCRG-10 are retained by the association JBCRG that conducted the study, and study subjects have no ownership rights over intellectual property. The provision of data for the present study will be funded from general donations received by the association JBCRG. There are no conflicts of interest that may affect the study results and interpretation. |
| Study organization | General Incorporated Association JBCRG Nihombashi-koamicho 9-4, Chuo-ku, Tokyo 103-0016, Japan TEL: 81-3-6264-8873 FAX: 81-3-6264-8875 |
| Details of participating medical institutions | JBCRG-09 (https://jbcrg.jp/clinicaltrials/479/) JBCRG-10 (https://jbcrg.jp/clinicaltrials/489/) |
| Study investigators | JBCRG-09 Principal investigators Masakazu Toi, M.D., Ph. D. Dept of Surgery (Breast Surgery), Graduate School of Medicine, Kyoto University 54 Shogoinkawaharacho, Sakyo-ku, Kyoto-shi, Kyoto 606-8507, Japan TEL: 81-75-751-3660 Norikazu Masuda, M.D., Ph. D. Dept of Surgery, Breast Oncology, NHO Osaka National Hospital 2-1-14 Hoenzaka, Chuo-ku, Osaka 540-0006, Japan TEL: 81-6-6942-1331 JBCRG-10 Principal investigators Masakazu Toi, M.D., Ph. D. Dept of Surgery (Breast Surgery), Graduate School of Medicine, Kyoto University 54 Shogoinkawaharacho, Sakyo-ku, Kyoto-shi, Kyoto 606-8507, Japan TEL: 81-75-751-3660 |

| | |
|---------|--|
| | <p>Norikazu Masuda, M.D., Ph. D. Department of Surgery, Breast Oncology, NHO Osaka National Hospital 2-1-14 Hoenzaka, Chuo-ku, Osaka 540-0006, Japan TEL: 81-6-6942-1331</p> <p>Takayuki Ueno, M.D., Ph. D. Breast Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital 3-8-31 Ariake, Koto, Tokyo 135-8550, Japan TEL: 81-3-3520-0111</p> |
| Remarks | |